Shanghai Henlius Biotech’s Privatization by Fosun Advances
Company Announcements

Shanghai Henlius Biotech’s Privatization by Fosun Advances

Shanghai Henlius Biotech, Inc. Class H (HK:2696) has released an update.

Shanghai Henlius Biotech is undergoing a pre-conditional privatization led by Fosun New Medicine, aiming to merge and absorb the company. The merger is progressing as the Offeror liaises with Chinese authorities to meet necessary pre-conditions. A delay in the dispatch of the composite document has been announced, with a new deadline set for May 2025.

For further insights into HK:2696 stock, check out TipRanks’ Stock Analysis page.

Looking for investment ideas? Subscribe to our Smart Investor newsletter for weekly expert stock picks!
Get real-time notifications on news & analysis, curated for your stock watchlist. Download the TipRanks app today! Get the App